---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-23-000023"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T04:25:10.029242+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Vertex appoints Michel Lagarde to board as tenth director

## Summary
- Michel Lagarde appointed to Vertex board effective Oct 5, 2023; board expands to 10.
- Lagarde is EVP and COO of Thermo Fisher Scientific; background in pharma services and private equity.
- Received $400,000 RSU award vesting in October 2024; standard non-employee director compensation.

## SEC filing metadata
- accession: 0000875320-23-000023
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532023000023/0000875320-23-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532023000023/vrtx-20231003.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-23-000023
- JSON: https://secwatch.observer/filing/0000875320-23-000023.json
- Plain text: https://secwatch.observer/filing/0000875320-23-000023.txt

## Key facts
- Executive change
  Michel Lagarde was appointed as Director at VERTEX PHARMACEUTICALS INC / MA.
  - Action: appointed
  - Role: Director
  source text: On October 3, 2023, Michel Lagarde was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”), effective on October 5, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532023000023/0000875320-23-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.